Objectives Diabetic presents higher ischaemic heart disease morbidity and mortality, lacking of effective strategies of prevention and cure.Recently, a small peptide, helix B surface peptide (HBSP), derived from erythropoietin (EPO) was developed and shown to be tissue protective but avoiding property of elevating red blood cell which might become additional cardiovascular risks for already vulnerable patients.